MIRXES-B (02629) announced that its indirect wholly-owned subsidiary MiRXES PTE. LTD. has recently entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO, a company listed on the Indonesia Stock Exchange under stock code CHEK. Under the agreement, both parties will collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia. The memorandum of understanding has a term of 12 months from the date of signing, inclusive.

Through the partnership with PT DIASTIKA BIOTEKINDO, the Group can: (i) immediately enter the Indonesian market through PT DIASTIKA BIOTEKINDO's existing channels by deploying blood-based microRNA or multi-omics testing equipment for high-incidence cancers such as gastric and lung cancers; (ii) leverage Indonesia's localization policies (including tax incentives for achieving 40% localization rates) and the ASEAN-centric medical device framework to achieve regulatory flexibility; and (iii) utilize Indonesia as a demonstration launch region to replicate the business across Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare infrastructures, thereby achieving global scale expansion.